ClinicalTrials.gg
RecruitingNCT07513038Updated Apr 6, 2026

Use of Indocyanine Green (ICG) for the Diagnosis of Biliary Atresia

A Phase 1/2 interventional study of Indocyanine Green (ICG) in Biliary Atresia, sponsored by Boston Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 0 Days to 3 Months. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Boston Children's Hospital · Phase 1/2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Aug 2024, registered Feb 2025).
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
0 Days to 3 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Biliary Atresia with a site in United States — 8 open to participants now, 10 under way, 2 of them phase 3. Biliary Atresia · United States.

Planned enrollment
10th of 14
20 · median 53
Started
2024
with 2 others
Phase 1/2
2 of 22
1 open now
Registered
21st of 22
by date
Lead sponsor
1 of 22
Boston Children's Hospital

Among the 22 studies in Biliary Atresia with a site in United States, this one is the 10th largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2024, is one of 2 in phase 1/2, and was the 21st registered.

Biliary Atresia

78 studies on the registry are indexed under Biliary Atresia; 26 are open to participants now.

Browse Biliary Atresia studies →

Open to participants now

8 of the 22 studies in Biliary Atresia with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Biliary Atresia studies recruiting now, 3 (14%) set no upper age limit and 18 (86%) stop at 75 or younger; 21 take children under 18; 6 take healthy volunteers.

This study: 0 Days to 3 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Biliary Atresia with a site in United States, or all of them as a file.
02

Study summary

Biliary atresia is a rare, progressive liver disease that only affects infants. It leads to complete obstruction and scarring of the bile duct. Current non-invasive diagnostic tests have limited sensitivity.

Indocyanine Green (ICG) is a non-radioactive, fluorescent compound with several clinical applications including angiography for ophthalmologic testing, visualization during surgery, and measurement of liver function. After excitation with near infrared light (750-810 nm), ICG emits near infrared light at 850 nm, which can be detected by a special camera. ICG is taken up by the liver exclusively and excreted in the bile, where it is removed from the body in the stool. The hypothesis is that after injection of ICG, participants with biliary atresia will not have any fluorescence detected in the stool. Investigators aim to use ICG as a functional test of bile duct patency in participants with cholestasis being evaluated for biliary atresia.

03

Conditions studied

  • Biliary Atresia

Browse trials for

04

Who can participate

Ages eligible
0 Days to 3 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age \<3 months viable infants
  2. cholestasis (defined as direct >1)
  3. undergoing diagnostic HIDA scan to evaluate for biliary atresia

Exclusion criteria

Exclusion Criteria

  1. kidney disease ( \<60 mL/min/1.73m2)
  2. grossly bloody stools
  3. history of bowel surgery or disease
  4. history of allergic reaction to ICG, iodine, or shellfish
  5. unable to provide
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Indocyanine Green (ICG)

    All infants enrolled in this study will receive an injection of ICG

    Drug: Indocyanine Green (ICG)

Interventions

06

What researchers measure

Primary outcomes

  1. Indocyanine green (ICG) fluorescence in stool

    We will assess if there is presence or absence of ICG fluorescence in the stool 24 hours after injection. This will be done using fluorescent imaging (Stryker) and result confirmed by two study staff.

    Time frame: 24 hours after injection

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Aug 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Apr 6, 2026
StartActual
Aug 1, 2024
Primary completionEst.
Aug 2026
CompletionEst.
Dec 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07513038
Responsible party
Andrew Wehrman (Primary Investigator, Boston Children's Hospital) — Principal investigator
First posted
Apr 6, 2026
Start date
Aug 1, 2024
Primary completion
Aug 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 6, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Indocyanine Green

Start the discussion